527 related articles for article (PubMed ID: 14512391)
41. Effect of levetiracetam on cardiac repolarization in healthy subjects: a single-dose, randomized, placebo- and active-controlled, four-way crossover study.
Hulhoven R; Rosillon D; Bridson WE; Meeus MA; Salas E; Stockis A
Clin Ther; 2008 Feb; 30(2):260-70. PubMed ID: 18343264
[TBL] [Abstract][Full Text] [Related]
42. Clinical activity of arsenic trioxide for the treatment of multiple myeloma.
Munshi NC; Tricot G; Desikan R; Badros A; Zangari M; Toor A; Morris C; Anaissie E; Barlogie B
Leukemia; 2002 Sep; 16(9):1835-7. PubMed ID: 12200700
[TBL] [Abstract][Full Text] [Related]
43. Comparing two arsenic trioxide administration methods in APL therapy.
Zhou J; Meng R; Yang BF
Chin Med J (Engl); 2004 Sep; 117(9):1411-3. PubMed ID: 15377438
[No Abstract] [Full Text] [Related]
44. Ventricular repolarization dynamics in arsenic trioxide treatment of acute promyelocytic leukemia.
Sun Y; Wang L; Que Y; Zhu H; Yang X; Li D
Int J Cardiol; 2020 May; 306():163-167. PubMed ID: 31761398
[TBL] [Abstract][Full Text] [Related]
45. Accuracy of uncorrected versus corrected QT interval for prediction of torsade de pointes associated with intravenous haloperidol.
Tisdale JE; Kovacs R; Mi D; McCabe GP; Cariera BL; Sharma N; Rosman H
Pharmacotherapy; 2007 Feb; 27(2):175-82. PubMed ID: 17253907
[TBL] [Abstract][Full Text] [Related]
46. Phase 2 study of arsenic trioxide in patients with relapsed or refractory multiple myeloma.
Hussein MA; Saleh M; Ravandi F; Mason J; Rifkin RM; Ellison R
Br J Haematol; 2004 May; 125(4):470-6. PubMed ID: 15142117
[TBL] [Abstract][Full Text] [Related]
47. Two cases of monocular visual loss during oral arsenic trioxide therapy of acute promyelocytic leukemia.
Au WY; Hon C; Yau K; Lai WW; Fong BM; Tam S; Kwong YL
Am J Hematol; 2009 Oct; 84(10):699. PubMed ID: 19705432
[No Abstract] [Full Text] [Related]
48. Psychotropic drugs associated with corrected QT interval prolongation.
van Noord C; Straus SM; Sturkenboom MC; Hofman A; Aarnoudse AJ; Bagnardi V; Kors JA; Newton-Cheh C; Witteman JC; Stricker BH
J Clin Psychopharmacol; 2009 Feb; 29(1):9-15. PubMed ID: 19142100
[TBL] [Abstract][Full Text] [Related]
49. Prevalence and clinical relevance of corrected QT interval prolongation during methadone and buprenorphine treatment: a mortality assessment study.
Anchersen K; Clausen T; Gossop M; Hansteen V; Waal H
Addiction; 2009 Jun; 104(6):993-9. PubMed ID: 19392907
[TBL] [Abstract][Full Text] [Related]
50. Superiority of an arsenic trioxide-based regimen over a historic control combining all-trans retinoic acid plus intensive chemotherapy in the treatment of relapsed acute promyelocytic leukemia.
Thomas X; Pigneux A; Raffoux E; Huguet F; Caillot D; Fenaux P
Haematologica; 2006 Jul; 91(7):996-7. PubMed ID: 16757416
[TBL] [Abstract][Full Text] [Related]
51. Non-lethal bone marrow necrosis under first-line arsenic trioxide therapy in acute promyelocytic leukaemia.
Ianotto JC; Tempescul A; Eveillard JR; Charles F; Berthou C
Acta Haematol; 2010; 123(3):146-7. PubMed ID: 20134156
[No Abstract] [Full Text] [Related]
52. A pharmacokinetic and safety study of intravenous arsenic trioxide in adult cancer patients with renal impairment.
Sweeney CJ; Takimoto C; Wood L; Porter JM; Tracewell WG; Darwish M; D'Andrea DM; Remick SC
Cancer Chemother Pharmacol; 2010 Jul; 66(2):345-56. PubMed ID: 19911123
[TBL] [Abstract][Full Text] [Related]
53. Retrospective analysis of 65 Chinese children with acute promyelocytic leukemia: a single center experience.
Zhang L; Zhao H; Zhu X; Chen Y; Zou Y; Chen X
Pediatr Blood Cancer; 2008 Aug; 51(2):210-5. PubMed ID: 18428427
[TBL] [Abstract][Full Text] [Related]
54. QTc abnormalities in deliberate self-poisoning with moclobemide.
Downes MA; Whyte IM; Isbister GK
Intern Med J; 2005 Jul; 35(7):388-91. PubMed ID: 15958107
[TBL] [Abstract][Full Text] [Related]
55. Arsenic trioxide in the treatment of haematological malignancies.
Kwong YL
Expert Opin Drug Saf; 2004 Nov; 3(6):589-97. PubMed ID: 15500417
[TBL] [Abstract][Full Text] [Related]
56. Arsenic derivatives in hematologic malignancies: a role beyond acute promyelocytic leukemia?
Verstovsek S; Giles F; Quintás-Cardama A; Perez N; Ravandi-Kashani F; Beran M; Freireich E; Kantarjian H
Hematol Oncol; 2006 Dec; 24(4):181-8. PubMed ID: 16783836
[TBL] [Abstract][Full Text] [Related]
57. Arsenic trioxide in recurrent urothelial cancer: a cancer and leukemia group B phase II trial (CALGB 99903).
Bajorin DF; Halabi S; Small E
Clin Genitourin Cancer; 2009 Oct; 7(3):E66-70. PubMed ID: 19815484
[TBL] [Abstract][Full Text] [Related]
58. Prolonged QTc intervals on admission electrocardiograms: prevalence and correspondence with admission electrolyte abnormalities.
Golzari H; Dawson NV; Speroff T; Thomas C
Conn Med; 2007 Aug; 71(7):389-97. PubMed ID: 17879860
[TBL] [Abstract][Full Text] [Related]
59. Arsenic trioxide associated toothache.
Siderov J; Duggan J
J Oncol Pharm Pract; 2010 Jun; 16(2):127-8. PubMed ID: 19525303
[TBL] [Abstract][Full Text] [Related]
60. [Arsenic trioxide: "a successful poison" in patients with acute promyelocytic leukemia].
Lengfelder E; Schultheis B; Büchner T; Hehlmann R
Dtsch Med Wochenschr; 2007 Feb; 132(7):330-6. PubMed ID: 17286223
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]